REG - Diaceutics PLC - Board Change Update

DiaceuticsAnnouncement

29/10/2024 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241029:nRSc0622Ka&default-theme=true

RNS Number : 0622K  Diaceutics PLC  29 October 2024

Diaceutics PLC - Board Change Update

Belfast and London, 29 October 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, today announces that following
the announcement on 1 October 2024 and completion of the usual Nominated
Adviser due diligence checks, Cheryl MacDiarmid is confirmed as having joined
the board as a Non-Executive Director.

 

The following information is disclosed in accordance with Schedule 2(g) of the
AIM Rules for Companies:

 

Additional information with regard to Cheryl MacDiarmid:

Cherly MacDiarmid (née Gaskin), age 56, is currently or has been a director
of the following companies within the past five years:

 

 

 Current Directorships     Former Directorships
 Allergy Therapeutics Plc
                           Phivco UK Limited
                           ViiV Healthcare UK (NO.6) Limited
                           ViiV Healthcare UK (NO.3) Limited
                           ViiV Healthcare UK (NO.5) Limited
                           ViiV Healthcare Trading Services UK Limited
                           ViiV Healthcare UK (NO.4) Limited
                           ViiV Healthcare Overseas Limited
                           ViiV Healthcare UK (NO.7) Limited
                           ViiV Healthcare Finance Limited
                           ViiV Healthcare UK Limited
                           Phivco UK II Limited

 

 

 Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer           Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer           investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)      Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 Alma Strategic Communications                   Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon                  diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFEMFSUELSEES